Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
Regular Job Code 8351PR Employee Class Civil Service Add to My Favorite Jobs Email this Job About the Job 70% In vitro experiments: Make and maintain neuronal cultures; Transfect the cultured neurons
-
particular device design and fabrication, drug conjugation, and in vitro and in vivo experimentation) are required. Proficiency in English is required. For consideration, applicants need to submit a cover
-
Vitro & In Vivo Models: Utilize advanced models (BBB models, rodent CNS injury/disease models) to assess delivery performance and safety. Analytical & Imaging Techniques: Apply quantitative imaging
-
2 $69,073-74,281 The posted UC salary scales set the minimum pay determined by rank and step at appointment. See Table [https://drive.google.com/file/d/1NOYsgsY3aDqvWGUMqrjwdbgcxx3aS5EQ/view
-
pathophysiological changes relevant to anhedonia. Develop models with high construct validity. Identify new targets to treat anhedonia. This may involve multi-modal approaches combining in vitro, in vivo, and in
-
the characterization of viral infections using advanced systems aimed at identifying potential markers of infection progression and characterizing candidate antiviral compounds in vitro. From a technical perspective
-
in T cell-based immunotherapy (it might include CAR T cells), including studies on in vitro T cell-cancer cell interactions demonstrated by the first authorship in a peer-reviewed publication. While
-
penumbra — the zone of partially injured but potentially recoverable neurons surrounding a brain infarct. Using advanced in-vitro models, we study how metabolic stress affects neuronal network function and
-
/researchers, and we work with amazing partners, including other Harvard Medical School-affiliated hospitals. The Fischer Lab (https://fischerlab.org/) seeks a highly motivated individual to join the team as a
-
Campus in Aurora, CO. The team’s research focuses on exploring antibiotic combinations to achieve mechanistic and therapeutic synergy against urgent clinical Gram-negative threats, using in vitro exposure